Time filter

Source Type

Mallo M.,IMIM Hospital del Mar Research Institute | Mallo M.,Spanish Hematological Cytogenetics Working Group | Mallo M.,Spanish MDS Registry Group | Mallo M.,Autonomous University of Barcelona | And 16 more authors.
Leukemia Research

The clone size has been postulated as a prognostic factor in myelodysplastic syndromes (MDS), though it has not been studied systematically. We tested its impact (<100% vs. 100%) in a population of 216 MDS with chromosome 7 abnormalities (-7/7q-) (n=84), trisomy 8 (n=99), 20q deletion (n=28) and loss of Y chromosome (n=26). Focusing on the survival the bad prognosis of -7/7q- was independent of the clone size (9.3 vs. 5.0 months, P=0.188, not significant) but trisomy 8 cases with 100% aberrant metaphases did reveal a worse prognosis (13.9 vs. 5.9 months, P=0.003). © 2011 Elsevier Ltd. Source

Mallo M.,Spanish Haematological Cytogenetics Working Group | Mallo M.,Autonomous University of Barcelona | Mallo M.,Spanish MDS Registry Group | Cervera J.,Spanish Haematological Cytogenetics Working Group | And 52 more authors.

This cooperative study assessed prognostic factors for overall survival (OS) and risk of transformation to acute myeloid leukemia (AML) in 541 patients with de novo myelodysplastic syndrome (MDS) and deletion 5q. Additional chromosomal abnormalities were strongly related to different patients characteristics. In multivariate analysis, the most important predictors of both OS and AML transformation risk were number of chromosomal abnormalities (P0.001 for both outcomes), platelet count (P0.001 and P0.001, respectively) and proportion of bone marrow blasts (P0.001 and P0.016, respectively). The number of chromosomal abnormalities defined three risk categories for AML transformation (del(5q), del(5q)1 and del(5q)2 abnormalities) and two for OS (one group: del(5q) and del(5q)1; and del(5q)2 abnormalities, as the other one); with a median survival time of 58.0 and 6.8 months, respectively. Platelet count (P0.001) and age (P0.034) predicted OS in patients with 5qsyndrome. This study demonstrates the importance of additional chromosomal abnormalities in MDS patients with deletion 5q, challenges the current 5qsyndrome definition and constitutes a useful reference series to properly analyze the results of clinical trials in these patients. © 2011 Macmillan Publishers Limited All rights reserved. Source

Discover hidden collaborations